By Louis Garguilo, Chief Editor, Outsourced Pharma
What industry trends, developments or outcomes did not shape up as you had expected at the start of 2018? Here are replies to this question from the Outsourced Pharma Editorial Advisory Board, starting with an insightful list from Darren Dasburg, VP, Head Learning and Development, Global Operations, AstraZeneca. Considering what didn’t work out should help us focus in 2019.
By Greg Weilersbacher, Eastlake Quality Consulting
Everyone is fascinated by new equipment, and the excitement is not limited to engineers and manufacturing technicians. To a CDMO, new equipment often translates to additional service offerings and higher-volume productions the company can use for fresh marketing content to attract new clients and return business from existing customers. To the sponsor, the CDMO’s new equipment could mean their next production may be able to start sooner than expected, or it might allow them to continue working with their existing CDMO rather than looking to the competition for the technology their product needs.
Data integrity is essential in the pharma, biologics, and medical device manufacturing industries. Not only is complete, accurate, and reliable data necessary to assure drug safety and quality, the growing reliance on increasingly sophisticated digital systems means that issues relating to data integrity are increasingly complex.
By Dr. Dirk Voelkel,GE Healthcare Life Sciences
By applying remote monitoring solutions, advanced modeling, and optimization of manufacturing processes, Industry 4.0 offers improved process reliability and product quality through unlimited possibilities of connecting machines and data.